Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Here We Go Again!

The only concern I have comes from the statement RG made in his letter.



"Patent re-examinations for 148, 336, 584 and 749 Late last year the USPTO began the patent re-examination process for four key patents in the MMP portfolio. This is a time-consuming, detailed process that can take months, even years. The company cannot forecast the progress nor the eventual outcome."



I think most investors, including myself, have always been under the impression that the '148/'336 reexams are the keys to the kingdom. That's why I found his statement to be curious considering the '148 is getting close and the '336 shouldn't be years away. If this is in relation to the '749 I would like for PTSC to explain the impact that particular patent has in the licensing process. When he starts speaking in terms of years it makes me think there could be some appeals in our future unless he is referring to the '749 specifically.

Share
New Message
Please login to post a reply